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Abstract
Background: In spite of the fact that pharmaceutical services are an essential component of all malaria
programmes, quality of these services has been little explored in the literature. This study presents the first results
of the application of an evaluation model of pharmaceutical services in high-risk municipalities of the Amazon
region, focusing on indicators regarding organization of services and prescribing according to national guidelines.
Methods: A theoretical framework of pharmaceutical services for non-complicated malaria was built based on the
Rapid Evaluation Method (WHO). The framework included organization of services and prescribing, among other
activities. The study was carried out in 15 primary health facilities in six high-risk municipalities of the Brazilian
Amazon. Malaria individuals ≥ 15 years old were approached and data was collected using specific instruments.
Data was checked by independent reviewers and fed to a data bank through double-entry. Descriptive variables
were analyzed.
Results: A copy of the official treatment guideline was found in 80% of the facilities; 67% presented an
environment for receiving and prescribing patients. Re-supply of stocks followed a different timeline; no facilities
adhered to forecasting methods for stock management. No shortages or expired anti-malarials were observed, but
overstock was a common finding. On 86.7% of facilities, the average of good storage practices was 48%. Time
between diagnosis and treatment was zero days. Of 601 patients interviewed, 453 were diagnosed for Plasmodium
vivax; of these, 99.3% received indications for the first-line scheme. Different therapeutic schemes were given to
Plasmodium falciparum patients. Twenty-eight (4.6%) out of 601 were prescribed regimens not listed in the national
guideline. Only 5.7% individuals received a prescription or a written instruction of any kind.
Conclusions: The results show that while diagnostic procedure is well established and functioning in the Brazilian
malaria programme, prescribing is still an activity that is actually not performed. The absence of physicians and
poor integration between malaria services and primary health services make for the lack of a prescription or
written instruction for malaria patients throughout the Brazilian Amazon. This fact may lead to a great number of
problems in rational use and in adherence to medication.
* Correspondence: marmutis@ioc.fiocruz.br
1Laboratório de Doenças Parasitárias, Instituto Oswaldo Cruz Fundação
Oswaldo Cruz, Av. Brasil 4365, Pavilhão Arthur Neiva, sala 21-B, CEP - 21040-
900, Rio de Janeiro, Brazil
Full list of author information is available at the end of the article
Suárez-Mutis et al. Malaria Journal 2011, 10:335
http://www.malariajournal.com/content/10/1/335
© 2011 Suárez-Mutis et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Background
Brazil today reports 50% of all malaria cases in the Amer-
icas Region and the Amazon accounts for 99.8% of all
cases in the country [1]. Over the years, fluctuations in
the number of malaria cases have occurred. However,
social changes and internal migration brought an upsurge
of malaria [2]. In 2005, there were more than 600, 000
reported malaria cases. With firm implementation of
control measures, by the Brazilian National Malaria Con-
trol Programme (PNCM), in 2009 the number of notifi-
cations dropped to 308, 000, reaching the specific 2010
Millennium Goal for malaria in the country [3].
The PNCM’s adopted control rationale focuses on early
diagnosis and adequate treatment, while also favouring
prevention strategies. All malaria actions are under the
responsibility of the Brazilian government. After 2003, the
federal control of malaria activities was transferred to state
and local (municipal) control. A network of malaria out-
posts in the Amazon region provides free microscopy
diagnosis, treatment with standard medicines and selective
vector control [4]. Lately, health education and delivery of
long-lasting impregnated bed nets was incorporated to
control strategies. By 2008, there were 3422 laboratories
for microscopy diagnosis and 48, 281 primary health care
agents for malaria care in 807 municipalities; in that year,
the number of high risk (API > 50) municipalities was 67
[5]. Almost 85% of malaria cases in the country are caused
by Plasmodium vivax. [1]. Although the emergence of
chloroquine resistance in Manaus (State of Amazonas) has
been reported [6], the treatment for P. vivax is still cen-
tered on the combination of chloroquine and primaquine.
Treatment for Plasmodium falciparum in Brazil had tra-
ditionally involved quinine sulphate, doxycycline and pri-
maquine. Growing resistance, complexity of regimen,
adverse effects and sub-optimal therapeutic effectiveness
[7] led to the introduction of an artemisinin-based combi-
nation therapy (ACT), at the end of 2006, by the PNCM
in some few municipalities. At the time of the study, the
first ACT combination was introduced, artemether-lume-
fantrine. With these new combinations, the proportion of
P. falciparum malaria cases decreased from 31% in 2002
to 15% 2009 [8].
The therapeutic use of anti-malarials may lead to non-
adherence, enhancing resistance and disease prevalence.
In this topic, quality pharmaceutical services are consid-
ered a key element for control, especially considering
the PNCM’s rationale [9].
In spite of the fact that pharmaceutical services are an
essential component of all malaria programmes, espe-
cially those that focus on early diagnosis and adequate
treatment, quality of pharmaceutical services for malaria
has been little explored in the literature. The most pub-
lished information concerns therapeutic regimens for
P. falciparum [10]. In fact, it is the need for quality ser-
vices, rather than the species, which should be the cen-
tral point of the argument [11].
In order to understand comprehensive pharmaceutical
services (such as the organization of services, prescribing
and dispensing) for malaria and other endemic diseases,
a theoretical outline composed of a logical model and a
framework was proposed as an evaluation model of these
services [12]. This study presents the first results of the
application of this evaluation model in six high-risk
municipalities of the Amazon region (Figure 1), focusing
on organization of services and prescribing according to
national guidelines.
Methods
The methodology is based on the theoretical framework of
the “Pharmaceutical services for non-complicated malaria
by P. vivax and P. falciparum in high-risk municipalities of
the Brazilian Amazon: organization of services, prescribing,
dispensing and adherence to treatment” The Mafalda Pro-
ject, published previously [12]. A broad review of pharma-
ceutical services for malaria was undertaken in the
literature, from 1980 to 2005 [10]. An analytical outline,
comprising the theoretical model and 25 indicators was
developed. These indicators included the following dimen-
sions: context and organization of pharmaceutical services,
prescribing, dispensing and adherence to treatment. This
paper will focus on the first two dimensions. Dispensing
and adherence will be developed in a forthcoming paper.
The investigative strategy was based on the Rapid Eva-
luation Method, proposed by the World Health Organi-
zation (WHO) [13] and adapted by Management
Sciences for Health (MSH) [14,15]. In evaluations of
non-complicated malaria a sample of not under 600
patient registries is recommended [16].
Study sites and sample
In Brazil, malaria control is based on early diagnosis and
treatment, which are entirely carried out by the National
Malaria Control Programme (PNCM). All healthcare for
malaria is universal and free and all facilities must adopt
the National Treatment Protocol (MTM). All treatment
regimens investigated in this paper followed the version
adopted at the time of the study [17].
The study was carried out in six malaria high-risk
municipalities of the Brazilian Amazon. The municipali-
ties were first selected according to API (Annual Parasitic
Index) greater than 50 cases per 1, 000 inhabitants, in
2005 and a count of, at least, 7, 000 cases of malaria per
year (in order to guarantee 150 patients consulted per
week in each municipality). Once these criteria were met
by all the high-risk municipalities, they were further
examined for the adoption of the 2001 national guideline
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(MTM) and the admission, by local health managers, that
a prescription or a written instruction was given to the
malaria patient. These criteria determined 15 eligible
municipalities in 4 states. The following step included
the stratification according to population size, in order to
cover possible differences in services structure. There-
fore, two municipalities with > 100, 000 inhabitants, two
with 99, 999 to 30, 000 inhabitants and two with < 29,
999 inhabitants were selected from the eligible municipa-
lities. The final choice was based on proximity, in order
to make field logistics in the Amazon easier.
Eligible health units were all primary health facilities and
health centers in municipal urban areas involved in Pri-
mary Health Care (PHC) and distancing not more than 50
km from city-center. In spite of the fact that two munici-
palities (Manaus and Porto Velho) harbored reference
centers for malaria, none were visited in this part of the
investigation. Health teams for malaria care were com-
posed mainly by health agents. Their training and experi-
ence is described elsewhere [18]. Up to four health
facilities were visited in each municipality in order to
attain the required number of patients per municipality.
The number of visited health facilities in each municipality
was not standardized since the chosen unit of analysis was
the municipality and not the health unit. Organization of
services focused on pharmaceutical services in primary
health care facilities and not on all levels of health care in
the municipality.
The investigation was limited to individuals of both
genders ≥ 15 years of age. Patients presenting with
symptoms confirmed by positive thick smear were fol-











Figure 1 Map of selected municipalities in the Brazilian Amazon. Six malaria high risk municipalities in the Brazilian Amazon were selected
for the study. Cruzeiro do Sul and Rodrigues Alves in the State of Acre, Manaus and Presidente Figueiredo in Amazonas and Porto Velho and
Ariquemes in the State of Rondonia. The election criteria were API (Annual Parasitic Index) greater than 50 cases per 1, 000 inhabitants (in the
previous year) and an ocurrence of at least 7, 000 cases of malaria per year (in order to guarantee 150 patients consulted per week). Finally, two
municipalities with > 100, 000 inhabitants (Manaus and Porto Velho), 2 with between 99, 999 and 30, 000 inhabitants (Ariquemes and Cruzeiro
do Sul) and 2 with < 29, 999 inhabitants (Presidente Figueiredo and Rodrigues Alves) were selected from eligible municipalities in the region.
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Data collection instruments
All data collection instruments (questionnaires, observa-
tion forms, interviews forms and charts review forms)
were prepared according to the theoretical framework
[12] and applied successively during project data collec-
tion. Interviews were conducted based on objective
questionnaires and interview forms for qualitative data.
Two different observation forms were used to collect
service data (organization of pharmaceutical services,
stock and management of anti-malarials) and to orga-
nize recruitment of individuals. A chart review form
compiled data on patient diagnoses, type of Plasmodium
spp and time from diagnosis to treatment. An additional
chart review form examined prescription data (compli-
ance to national guideline). Direct observation was also
undertaken by field researchers for examination of stock
management and of pharmaceutical services routines.
Pilot study
A pilot study was conducted in a high-risk municipality
not on the study sample (Tucuruí, Pará), in order to
apply and adjust the methodology and the data collec-
tion instruments.
Field study
Research teams were trained on project objectives and
on data collection procedures and instruments in order
to increase internal consistency and reliability of data
collection. Two teams were deployed, each visiting three
different municipalities. Data collection took approxi-
mately 10 days for each municipality. Previous contact
was established with all malaria managers and written
consent was given before visits. Researchers were
instructed to start by visiting the local health service to
engage in a person-to-person explanation of the study
and to broker an overall receptive environment for the
investigation.
Investigation started with organization of pharmaceu-
tical services in municipalities and in health facilities.
Malaria consultation days were determined for optimal
patient recruitment. Before recruitment, patients were
asked to participate and consent was given through a
written statement.
Data analysis and statistical procedures
Data was checked by independent reviewers and fed to a
data bank (built in Access for Windows®, Microsoft
Corp., 2007) through double-entry. Inconsistencies were
verified and corrected. Data was descriptively analysed
and tabulation was used to organize main results.
Ethical considerations
This study was approved by the Ethics in Reasearch
Committe of the Sergio Arouca National School of
Public Health, Oswaldo Cruz Foundation (Fiocruz).
(Approval number 91/06; CAAE 0086.0.031.000.06)
Results
Context and pharmaceutical services organization
The 2007 API classified the studied municipalities as high
malaria risk, except for Manaus (AM) and Ariquemes
(RO), which had been high-risk in 2005. However, malaria
distribution was not homogeneous, varying from 28.7/
1000 inhabitants in Manaus to 572.8/1000 inhabitants in
Rodrigues Alves. In 2008, there was a decrease in the
number of malaria cases in all the municipalities, but
Rodrigues Alves (AC), Cruzeiro do Sul (AC) and Presi-
dente Figueiredo (AM) were still stratified as high-risk
malaria areas. In all municipalities, P. vivax was the most
prevalent Plasmodium both in 2007 and in 2008 (Table 1).
Pharmaceutical services organization were evaluated
according to indicators stemming from the “Mafalda” logi-
cal model [12]. Fifteen facilities were investigated in six
municipalities (Ariquemes, Cruzeiro do Sul, Manaus,
Porto Velho, Presidente Figueiredo and Rodrigues Alves
(Figure 1). Of these, 12 (80%) presented a copy of the offi-
cial guideline for malaria treatment (Manual de Terapêu-
tica da Malária - MTM). Availability of other, additional
instruction material, such as pamphlets produced by the
PNCM or by the state health service, in order to offer
information on the recently introduced anti-malarial treat-
ment with ACT, was detected in 13 of 15 (or 87%) facil-
ities. Ten out of 15 (67%) facilities presented an
environment for receiving patients and for prescribing.
The availability of complete treatments for P. vivax and
P. falciparum was estimated considering that primaquine,
at the time, was used for both treatments in different total
doses. The same amount of medicine would treat one
patient for P. vivax and 4.6 patients with P. falciparum. In
each municipality re-suply of stocks followed a different
timeline (monthly, weekly and daily re-stock routines were
observed), but it was evident that none of them adhered to
forecasting methods for stock management. As a result, in
spite of the fact that no shortages were observed for any
anti-malarial, overstock was a common finding. In Manaus
and in Porto Velho, quinine sulphate was overstocked,
while Manaus, Porto Velho and Ariquemes presented
overstock of doxycycline. Chloroquine and primaquine
were overstocked in Presidente Figueiredo, considering
regimens for both species.
Adequate storage practices were evaluated using a 10-
item checklist (Table 2). Only two of the 15 facilities
had separate storage and dispensing areas. These two
storage areas scored only 70% of good practices while
the corresponding dispensing areas scored 90% and
60%. All other 13 facilities presented medicine stocks
only in dispensing areas. In these, the average good sto-
rage practice score was 48%. Porto Velho scored worst
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among all municipalities, because facilities presented a
meager 30% average in good storage practices.
No expired anti-malarials were found, in any facility.
All 601 reviewed treatments were indicated by health
staff and dispensed after laboratory results, but in 24
(4%) cases species was not determined and treatment was
empirical. Average time between diagnosis and treatment
was zero days, i.e., thick smear was made immediately on
arrival at the health facility. Of laboratory-diagnosed
patients in which species was identified, 453 were diag-
nosed for P. vivax, 120 for P. falciparum, two for mixed
malaria (P. vivax + P. falciparum), two other species and
24 were not identified.
Of 63 health workers and health professionals involved
in malaria treatment at the 15 facilities, only one was a
medical doctor, stationed in Presidente Figueiredo. All
professionals and workers presented some level of training
for malaria care, but the level of knowledge and quality of
practice varied, reflecting upon their perceptions as to
diagnosis, treatment regimens, interaction with patients,
and responsibilities [18].
Prescribing and adherence to national guidelines
Prescribing practices were also evaluated according to
the “Mafalda” study [12]. A total of 601 patient charts
were reviewed at the 15 health facilities and when
possible prescribing underwent observation. Of these, in
only 34 cases (5.7%), patients received a prescription or
a written instruction of any kind on how to take their
medicines. In Ariquemes, Cruzeiro do Sul, Porto Velho
and Rodrigues Alves none of the patients received pre-
scriptions. In Manaus 20/128 (15, 6%) individuals
received written instructions and in Presidente Figueir-
edo, the only municipality where a doctor attended to
malaria patients, prescriptions were issued to 14 in 91
patients (15, 4%).
In relation to treatment indications according to
national guidelines, of the 453 (75.4%) patients diagnosed
for P. vivax malaria, indications for first-line scheme
(chloroquine and primaquine) were passed to 450
(99.3%) patients. Of the 120 patients (20.0%) diagnosed
with P. falciparum malaria, first-line treatment (quinine-
doxycycline-primaquine) was indicated to 57 (47.5%)
patients. Three (2.5%) patients were medicated with
mefloquine and primaquine (second-line treatment
scheme) and 26 (21.7%) with lumefantrine-artemether.
Of the 34 patients that received indication for other
treatments not officially sanctioned by the Ministry of
Health, 27 (22.5%) were medicated with a new ACT com-
bination (mefloquine-artesunate) under study by the
PNCM at the time, in Cruzeiro do Sul (AC). No informa-
tion was available on treatment indicated for seven
Table 1 Distribution of malaria cases in 2007 and 2008 in selected municipalities of the Brazilian Amazon
2007 2008
Municipality Population Cases API % vivax % falciparum Cases API % vivax % falciparum
Rodrigues Alves, AC 13.460 7.710 572, 8 81, 2 19, 2 3.118 231, 6 82, 2 17, 8
Cruzeiro do Sul, AC 77.004 28.339 368, 0 80, 5 19, 5 15.407 200, 1 83, 0 17, 0
Manaus, AM 1.738.641 49836 28, 7 88, 9 11, 7 24.974 14, 4 86, 2 13, 8
Presidente Figueiredo, AM 26.282 4.311 164, 0 86, 0 14, 4 3.235 123, 1 89, 5 10, 5
Ariquemes, RO 85.541 3.618 42, 3 72, 0 28, 0 2.194 25, 6 79, 7 20, 3
Porto Velho, RO 382.829 32.934 86, 0 78, 9 21, 1 23.648 61, 8 85, 4 14, 6
API: Annual Parasitic Index
Source: Virtual Health Library. Ministry of Health. Brazil.
Table 2 10-point checklist for evaluating storage practices for anti-malarials
NUMBER ITEMS
1 Space and surface areas are clean and free of dust.
2 Space (roofs, floors, countertops and walls) present adequate conditions for cleanliness and orderliness (light-colored, washable, easy-to-
clean) and for maintenance (moisture-free, water-protected, properly sealed).
3 Space provides proper air circulation (e.g. ceiling space at least 3 meters high, vents, exhaust fans etc.)
4 Space provides temperature-control (e.g., air-conditioning).
5 Products are protected from direct sunlight (e.g. windows are painted, curtains or shades are provided).
6 Medicines are stored with no contact with floor or walls (for which shelves, pallets etc are provided.).
7 Medicines are stored methodically (e.g., alphabetically, by therapeutic class, by expiry date etc).
8 Space is free of pests (insects, birds, rodents, marsupials etc.).
9 Fire extinguishers are operational, with valid expiry date and access to them is clear.
10 There is an inventory control system
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(5.8%) patients. Of recommended anti-malarials, dosage
forms and concentrations followed MTM 2001 specifica-
tions. Twenty-eight (4.6%) out of 601 were prescribed
either for regimens for other types of malaria or empiri-
cally for regimens not listed in the national guideline.
Discussion
Malaria, as a public health priority, is an important focus
point for development of quality pharmaceutical services,
and can serve as a model for other endemic diseases in
tropical areas of the world. This study encompassed a
special period for the PNCM, since the 2001 guideline
was being reviewed and new ACT schemes were being
introduced for P. falciparum.
The assumptions in studying pharmaceutical services in
high-risk municipalities were simple. First, the Brazilian
control strategy is based on diagnosis and treatment, mak-
ing pharmaceutical services essential. Second, pharmaceu-
tical services must be organized in those endemic diseases
areas where health needs are critical. Third, it is important
to study highly endemic areas, as services are apt to be
more structured and organized that in others where preva-
lence is low and the disease is not perceived as a health
risk. Finally, the choice of municipalities was intentionally
made to include not only incidence, but different popula-
tion magnitude, to reflect municipal diversity in the Brazi-
lian Amazon.
Although choice of municipalities may be perceived as
a limitation of this study and may have implications on
generalization of results, especially for rural areas, the
results may be applicable to urban areas in the Brazilian
Amazon. Furthermore, the effort was made to give a
comprehensive view of organization of services and of
prescribing in municipalities of various population sizes
once it was estimated that population size was a good
predictor for services organization [12].
Results showed that P. vivax malaria is the most pre-
valent species found in the visited municipalities, repeat-
ing the pattern observed in the Brazilian Amazon [5].
Manaus and Ariquemes, which had been high-risk
municipalities in 2005, were excluded from this category
in 2007 (Table 1). Number of cases dropped consider-
ably in all municipalities in 2008. However, only these
two maintained their high-risk-free status.
It was observed that 80% (12/15) of facilities had an
available copy of the 2001 official guideline for malaria
treatment and this is a positive indicator of quality of
care. Nevertheless the guideline itself had problems,
since it was based on limited pharmaceutical and clinical
evidence [10]. In 2010, the PNCM published new guide-
lines with better quality and based on more consistent
and locally-generated scientific evidence [8].
Additionally, 87% of health services had other instruc-
tional material. However this information had not been
disseminated to all the health workers in the area [18].
An especially critical issue in rational medicines use is
availability of information, for users and for health pro-
fessionals alike. Uninformed health professionals may be
unable to treat patients adequately. Reports show that
with appropriate information even patients with little
education were able to follow treatment with arte-
mether-lumefantrine, without supervision [19,20].
Another positive aspect was that no expired anti-malar-
ials were found. Nonetheless, overstock was detected and
none of the municipalities adhered to forecasting meth-
ods of stock management. None of the health facilities
fulfilled 100% of good practices in storage and dispensing
areas. As was to be expected, re-supply of stocks followed
no discernible routines, in spite of a perceived sense of
urgency in making treatment available. Forecasting activ-
ities are an essential part of pharmaceutical services orga-
nization. This aspect is tantamount, especially in the
Amazon, where humidity and temperatures are very high
most part of the year. In fact, a sampling of anti-malarials
from Brazilian treatment facilities was submitted to
quantitative analytical assays and presented problems in
concentration of the active principles [21]. The evidence
suggests that if in urban areas this situation was detected,
in rural regions, where facilities may be less than ade-
quate, with deficiencies in storage and dispensing areas,
where staff is possibly lacking and large distances may
cause supply shortages, the situation should be worse, as
has been cited in the literature [22,23].
In respect to diagnostic coverage, this study showed
that all individuals were submitted to laboratory confir-
mation of malaria and that in only 24 patients (4%) spe-
cies was not identified and that these were given
empirical treatment. In spite of reflecting only urban
areas, this operational indicator showed good perfor-
mance, following WHO recommendations (at least 90%
of suspected malaria outpatient cases should undergo
laboratory diagnosis-thick smear or Rapid Diagnostic
Test) [24]. Different results are reported from some
African countries, where laboratory diagnostic coverage
revolved from 33% to 40% [25,26], while in other set-
tings 60% of patients have no access to diagnosis [27].
Maybe the failures in diagnosis were due to probable
test error. Albeit considered simple and less technologi-
cally intense that other laboratory methods, the thick
smear may be a tricky technique. It is prone to consider-
able inter-observer variation, while requiring continuous
training of staff, as well as minimum laboratory infra-
structure [28]. Brazil has recently introduced a new
career for health workers, that of “microscopy techni-
cian”, to give professional incentives to health technicians
working in malaria [29], decreasing rapid turnover of
staff in endemic areas and consequently favoring diag-
nostic quality.
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The findings of this study show that patients have
close to immediate access to microscopic diagnosis. The
average time between diagnostic and treatment was 0
days. This was considered an excellent result, consider-
ing other examples in the literature [30]. In the state of
Amazonas 57% of patients are offered treatment within
48 hours of symptoms. In Rondonia and in Acre, the
proportions are 65% and 71% respectively. The national
Brazilian average is 59% [31]. The findings may reflect
the urban scenario depicted in the study.
Complete regimens for both P. vivax and P. falciparum
were readily available in the visited facilities. For P. vivax
patients, treatment indication according to the national
guidelines was successful, while for P. falciparum patients
were offered more alternatives. During the study period
only one first-line regimen for uncomplicated malaria in
adults was recommended for P. vivax. For P. falciparum,
the guideline offered two alternatives, because of Plasmo-
dium resistance and a third as consequence of introduc-
tion of ACTs in Amazonas.
Nonetheless, a percentage of treatments did not comply
with the national guidelines. While one ACT fixed-dose
combination was being introduced in Amazonas, another
was undergoing clinical field study in Acre - an interven-
tion involving 17, 000 patients and sponsored by The Bra-
zilian Ministry of Health and by Ravreda (Rede Amazônica
de Vigilância de Resistência aos Anti-maláricos) [4]. The
tentative incorporation of ACT to the treatment guideline
was, therefore, not uniform throughout the Amazon. The
low number of empirical treatments was due to diagnostic
failure and not to inobservance of the national protocol.
Only 5.7% of individuals with malaria received prescrip-
tions or written information on treatment regimens. Only
one medical doctor was identified among 63 health work-
ers involved in malaria treatment in the six study sites.
These facts reflect part of the malaria care-giving urban
scenario in Brazil. Nonetheless, in reference centers for
malaria in the Brazilian Amazon, all individuals with
malaria are attended to by medical doctors [32]. Brazilian
Health System and PNCM policy recommends that better
clinical evaluation of each case should be guaranteed
through physician-attended care. Therefore, it is difficult
to accept that in the visited municipalities a lesser stan-
dard of care should be acceptable. Decentralized health
interventions have been considered as advances of the Bra-
zilian Health System, in regard to access for users and
accountability for municipal managers, but differences in
revenue, demographics, health indicator performance and
in quality of management result in better or worse malaria
control [4].
In spite of the fact that one of the inclusion criteria
was the availability of a prescription or a written
instruction to the patient, this was not observed in the
field. The existence of a medical prescription is a very
important concern since malaria should be treated with
a combination of drugs, and the therapeutic scheme
depends on the parasitic species, patient age group and
clinical severity of the disease. Moreover, many malaria
patients have little formal education [33] and the com-
plexity of the therapeutic regimens for both P. vivax and
P. falciparum may baffle them. They rely on family or
friends to help with treatment schemes, making a clear
readable prescription therefore important to enhance
adequate adherence to a complete treatment [34,35].
The lack of a formal prescription may have, therefore,
made the actual treatment regimen given to each patient
difficult to detail, since the study relied mostly upon
observation and chart reviews.
It is possible to hypothesize that the rest of non-ACT/
non-protocol treatments for P. falciparum may have
been caused by the lack of medical doctors and pharma-
cists and by deficient training of other health profes-
sionals. Trained staff could nullify or bar inadequate
medicines indications. Adherence to therapeutic guide-
lines goes hand in hand with capacity building of health
staff and available information on treatment [22,25].
Only two thirds of the visited facilities presented a
specific area for receiving and consulting patients. In
pharmaceutical services, a proper environment for
patient dispensing and counseling is a determinant in
the patient’s understanding of the treatment regimen
and of possible adverse effects caused by medicines. Lay-
out of patient facilities is recognized as fundamental in
guaranteeing better patient comprehension [25]. This, in
turn, may lead to good or bad adherence to treatment
[33].
It is worthwhile to point out that a specific pro-
gramme for malaria with a separate structure of phar-
maceutical services, although helping to focus and
prioritize disease needs, may be more difficult to man-
age. In Brazil, municipalities are responsible for primary
healthcare. Although legislation has been passed stres-
sing the importance of combining efforts between pri-
mary health care (PHC) and malaria [36], joint work is
absent or lacking in most municipalities. The fact that
the PNCM is a vertical programme within the Ministry
of Health and centrally managed in regard to procure-
ment is not an excuse for the problems observed in
pharmaceutical services. Other vertical programmes
have shown a better capacity for integration with PHC
[37]. Pharmaceutical services would profit by viewing
malaria from the perspective of PHC since all phases,
from forecasting to rational use of medicines, apply to
both. The literature has observed that difficulties in
malaria control are greater where integrations with PHC
is lacking [38].
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Conclusions
Malaria is a public health priority. The Millennium Goals
and the Roll Back malaria partnership state that, by 2015,
total malaria cases have to be reduced to levels 75% lower
than those of the year 2000 [39,40]. In Brazil, the reduc-
tion goal for 2010 has been achieved [5], but because
malaria is such a recurrent disease, with a complex biolo-
gical cycle, and strongly influenced by social and economic
determinants, this result only warrants the need to
strengthen basic health and malaria services.
According to Greenwood [41], malaria cannot be elimi-
nated if quality of health systems which deliver care and
treatment is not accomplished first. There has been con-
siderable research directed to the eradication/elimination
of the disease, in the form of R&D of new molecular enti-
ties active against Plasmodium spp or vaccines; but
research on health services for malaria is equally impor-
tant and noteworthy. In programmes where treatment is
tantamount, pharmaceutical services research must be
acknowledged as fundamental. In respect to them, few
reports are available in the literature [26].
The visited facilities presented problems with organiza-
tion of services - especially concerning stock management
and storage. It was decided not to include rural areas,
resulting in exclusion of rural health units. In spite of this
limitation, in urban areas - where patients have better
access to health services and more formal schooling - better
facilities and services are expected. It is suggested that the
organization of pharmaceutical services in rural malaria ser-
vices may be worse. Additionally, the visited municipalities
accounted for an important percentage of malaria cases in
2006-2007, and in them malaria is one of the main health
problems. Because of this, it could be considered that
malaria services and pharmaceutical services for malaria in
these municipalities should have shown a higher level of
organization.
These results show that while diagnostic procedure is
well established and functioning in the PNCM, prescribing
is still an activity that is actually not performed. The
absence of physicians and the poor integration between
malaria services and primary health care make for the lack
of a prescription or written instruction for malaria patients
in several high-risk municipalities in the Brazilian Ama-
zon. This fact may lead to a great number of problems in
rational use and in adherence to medication.
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